REG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Filing of form 10-K for FY ended December 31, 2023

MaxCyteAnnouncement

13/03/2024 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240313:nRSM6065Ga&default-theme=true

RNS Number : 6065G  MaxCyte, Inc.  13 March 2024

 

 

MaxCyte announces filing of Form 10-K for the full year period ended December
31, 2023

 

ROCKVILLE, MD, March 13, 2024 - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a
leading, cell-engineering focused company providing enabling platform
technologies to advance the discovery, development, and commercialization of
next-generation cell therapeutics and innovative bioprocessing applications,
today announced that it has filed a Form 10-K with the SEC for the full year
period ended December 31, 2023.

A copy of the Form 10-K is available to view on the SEC's website
at www.sec.gov (http://www.sec.gov/)  and has also been posted to the
"SEC filings" page of the Company's website, https://investors.maxcyte.com/
(https://investors.maxcyte.com/) .

About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of
cells to improve patients' lives. We have spent more than 20 years honing our
expertise by building best-in-class platforms, perfecting the art of the
transfection workflow, and venturing beyond today's processes to innovate
tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow
Electroporation® technology, has been designed to support the rapidly
expanding cell therapy market and can be utilized across the continuum of the
high-growth cell therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The ExPERT family
of products includes: four instruments, the ATx™, STx™, GTx™ and VLx™;
a portfolio of proprietary related processing assemblies or disposables; and
software protocols, all supported by a robust worldwide intellectual property
portfolio. By providing our partners with the right technology platform, as
well as scientific, technical, and regulatory support, we aim to guide them on
their journey to transform human health. Learn more at maxcyte.com
(https://maxcyte.com/) and follow us on Twitter
(https://twitter.com/i/flow/login?redirect_after_login=%2FMaxCyte_info) and
LinkedIn (https://www.linkedin.com/company/maxcyte-inc-/) .

 

MaxCyte Contacts:

 

 US IR Adviser                                    +1 415-937-5400

 Gilmartin Group                                  ir@maxcyte.com (about:blank)

 David Deuchler, CFA
 US Media Relations                               +1 408-497-8568

 Seismic

 Valerie Enes

 Nominated Adviser and Joint Corporate Broker     +44 (0)20 7886 2500

 Panmure Gordon

 Emma Earl / Freddy Crossley

 Corporate Broking

 Rupert Dearden

 UK IR Adviser

 ICR Consilium                                    +44 (0)203 709 5700

 Mary-Jane Elliott                                maxcyte@consilium-comms.com (about:blank)

 Chris Welsh

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DOCSFISSDELSEFD